By Laurence Capron and Will Mitchell
Though it has been widely available for only a few days, mounting complaints over Apple’s new mapping application, seen as a poor substitute for the Google Maps application that it replaces, are tarnishing the launch of the iPhone5.… Read more
Permanent link to this article: http://blog.insead.edu/2012/10/why-apple-made-the-right-call-on-apple-maps/
Many organizations have started using social media tools internally to interact with their employees. However, the majority of companies have either stayed away from using these tools or failed to see satisfactory results. In fact, in our survey of 1060 global executives, only 30% said that they work for companies that benefited from the internal use of social media.… Read more
Permanent link to this article: http://blog.insead.edu/2012/09/use-social-media-to-develop-emotional-capital-with-your-employees/
Written by Nicolas Harlé, Philippe Ombregt and Karel Cool
With more than 90% of global GDP growth coming from the rapidly developing economies,[2] companies from around the world are targeting these markets for future expansion. The BRIC (Brazil-Russia-India-China) cluster has been a major magnet as it represents about 25% of global GDP and over 60% of global growth.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/merger-control-and-practice-in-the-bric-countries-vs-the-eu-and-the-us-review-thresholds/
By Laurence Capron & Will Mitchell
Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. Most of its sales are in the developing world (including 40% in Africa) — where it sells its HIV drugs for about $350 per year per patient — yet it is as profitable as the pharma giants of Europe, North America, and Japan.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/the-company-outsmarting-big-pharma-in-africa/
By Laurence Capron and Will Mitchell
Historically, big pharma firms made their own drugs. They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves.… Read more
Permanent link to this article: http://blog.insead.edu/2012/08/big-pharmas-mixed-modes-of-growth/
By Laurence Capron & Will Mitchell
Companies tend to repeat what has worked for them in the past. In our research on the telecom industry, for example, we found that the great majority of the executives we surveyed preferred internal development to external sourcing when they needed to develop differentiated products and services.… Read more
Permanent link to this article: http://blog.insead.edu/2012/07/when-to-change-a-winning-strategy/
The newly appointed CEO of Carrefour, M. Georges Plassat, has given himself three years to rebalance the Carrefour Group. Describing Carrefour as a “duck without a head”[i] – and thus no vision –, he is certainly aware of the challenge he is up to. … Read more
Permanent link to this article: http://blog.insead.edu/2012/06/carrefour-the-new-kmart/
Written by Karel Cool, Nicolas Harlé and Philippe Ombregt
With more than 90% of global GDP growth coming from the rapidly developing economies,[i] companies from around the world are targeting these markets for future expansion. The BRIC (Brazil-Russia-India-China) cluster has been a major magnet as it represents about 25% of global GDP and over 60% of global growth.… Read more
Permanent link to this article: http://blog.insead.edu/2012/06/merger-control-and-practice-in-the-bric-countries-the-facts/
